simvastatin + vitamin D3

This combination therapy consists of simvastatin, a small molecule HMG-CoA reductase inhibitor (statin), and vitamin D3 (cholecalciferol). Investigated by Dr. Rami Burstein at Beth Israel Deaconess Medical Center and Harvard Medical School, the regimen involves 20 mg of simvastatin and 1000 IU of vitamin D3 taken twice daily. The therapy is intended for the prophylactic treatment of episodic migraine in adults, leveraging the potential synergistic anti-inflammatory and immunomodulatory effects of both components. A Phase 2 clinical trial demonstrated that participants using this combination experienced significantly fewer migraine days compared to placebo, with a responder rate of 29% at 24 weeks. This approach represents an investigational use of existing generic medications rather than a novel branded drug product.

Other names

simvastatin and vitamin D3 for migrainesimvastatin and vitamin D for migraine prophylaxissimvastatin and vitamin D3